Oncolytics Biotech Inc T.ONC

T-Vec

[lonc17]

Many of you will remember T-Vec as (formerly) a strong competitor in the OV field. 

These latest results from a T-Vec trial show that ONC is far more successful. 

I am concerned that Pfizer let the 90 day exclusivity period exprire without presenting a meaningful offer, but I can wait a few more weeks/months and hope for the best. 

https://www.esmoopen.com/article/S2059-7029(23)00104-7/fulltext

[Noteable]

I've posted some of the possible reasons why Pfizer has been slow in their M&A activities. Perhaps I wasn't clear enough for some.

[Lesalpes29]

Speculation only... interest is high or not? Biding war or not... not enough good results to create a war actually! Always pushed an other year... an other six months... can we believe them... lot of speculation but it's still weak. GL

[Buckhenry]

the pumpers have been over zealous on this stock for quite some time. I told youins to take a more realistic approach with your expectations. I think this stock has good prospects of going up at some point in the future but I dont expect the moon her.  

[Noteable]

The problem with the Phase 1b T-Vec study is that the two I/O agents were administered simultaneously on day 1. As a result the immune system couldn't be primed for the action of the immune checkpoint inhibitor, as has been fulky discussed on this message board .. so the antitumor effect was negligible. Too bad some researchers haven't figured this out yet. 

[Noteable]

Should read .."fully discussed" on this message board.  As had been repeatedly stated in the past the positive effects of ONCY's pelareorep in combination with other I/O agents such as immune checkpoint inhibitors I'd that pelareorep "primes" the immune system in advance of the administration of a PD-(L)1 inhibitor, for example, by remodeling the tumor

[Noteable]

Lastly, T-Vec was administered intratumorally via intrahepatic injection and cannot be administered intravenously, which then severely impairs T-Vec'a ability to affect tumor mass any distance away from the intratumoral injection site.  Consequently these findings will certainly affect those OV companies who are currently employing herpes virus to treat liver cancer via an intratumoral